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a  b  s  t  r  a  c  t
Pharmaceutical  investigators  are  searching  for  preclinical  models  closely  resembling  the  original  cancer
and predicting  clinical  outcome.  This  study  compares  drug  response  of three  in  vitro  3D-drug  screening
models  with  different  complexity.
Tumor  cell  line  spheroids  were  generated  from  the cell  lines Caco-2,  DLD-1,  COLO  205, HT-29  and
HCT-116,  and  treated  with clinically  relevant  combination  therapies,  namely  5-FU/oxaliplatin  (FO),
5-FU/irinotecan  (FI)  and  the  molecular  drugs  Cetuximab,  Trastuzumab,  Vorinostat  and  Everolimus.  Treat-
ment  results  were  compared  with  spheroids  originated  from  tumor  cell  lines  (Caco-2,  DLD-1)  co-cultured
with stromal  cells  (PBMCs,  cancer-associated  ﬁbroblasts  of colorectal  origin)  and  spheroids  directly
prepared  from  colon  cancer  tissues.
Different  microenvironment  compositions  altered  the  tumor  cell  line  spheroid  response  patterns.
Adding  PBMCs  increased  resistance  to FO treatment  by 10–15%  in  Caco-2  and  DLD-1  spheroids  but
decreased  resistance  to  FI  by  16%  in  DLD-1  spheroids.  Fibroblast  co-cultures  decreased  resistance  to  FI in
Caco-2  spheroids  by  38% but  had  no impact  on  FO.  Treatment  of colon  cancer  tissue  spheroids  revealed
three  distinct  response  pattern  subgroups  not  detectable  in 3D cell  lines  models.
The  cancer  tissue  spheroid  model  mimics  both  tumor  characteristics  and  the  stromal  microenviron-
inval
ublisment  and  therefore  is an  
©  2015  The  Authors.  P
. Introduction
Preclinical cancer models predicting clinical treatment outcome
re urgently required in early drug development. Currently much
ffort is being spent on the development of reﬁned preclinical mod-
ls, in vitro as well as in vivo, to bridge the gap between successful
reclinical studies and success in clinical trials.One of the key players impacting drug efﬁcacy is the tumor
icroenvironment (Hanahan and Weinberg, 2011). A number of
actors such as hypoxia and acidosis, complex interactions between
Abbreviations: FO, 5-FU+oxaliplatin; FI, 5-FU+irinotecan; FOC/FIC, FO/FI+
etuximab; TILs, tumor inﬁltrating lymphocytes; TAMs, tumor associated
acrophages; TAFs/CAFs, tumor/cancer associated ﬁbroblasts; CRC, colorectal
ancer.
∗ Corresponding author at: SpheroTec GmbH, Am Klopferspitz 19, 82152 Martin-
ried, Germany. Tel.: +49 (0) 89 540 413 40.
E-mail addresses: ohoffmann@spherotec.com (O.I. Hoffmann),
ilmberger@spherotec.com (C. Ilmberger), smagosch@spherotec.com
S. Magosch), mareile.joka@med.uni-muenchen.de (M.  Joka),
arl-walter.jauch@med.uni-muenchen.de (K.-W. Jauch), bmayer@spherotec.com
B. Mayer).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.jbiotec.2015.02.029
168-1656/© 2015 The Authors. Published by Elsevier B.V. This is an open access article unuable  screening  model  for pharmaceutical  drug  development.
hed  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cancer cells and different stromal cell types as well as the extra-
cellular matrix and various soluble factors have been associated
with both drug resistance and sensitization. In addition, the tumor
microenvironment has been previously associated with changes
in biomarker expression on cancer cells, which is important for
patient stratiﬁcation in targeted therapy. Stromal cell types that
are interesting especially with regard to treatment efﬁcacy include
the tumor endothelial cells, the tumor inﬁltrating lymphocytes
(TILs), the tumor associated macrophages (TAMs) and the tumor
associated ﬁbroblasts (TAFs, CAFs). All these cell types are targets
of new treatment strategies aimed at the tumor stroma (Correia
and Bissell, 2012; Hanahan and Coussens, 2012; Zhang and Liu,
2013; Santoni et al., 2013; McMillin et al., 2013; Kyi and Postow,
2014).
The complexity, heterogeneity, plasticity and diversity of the
human tumor microenvironment cannot be replicated in pre-
clinical 2D tumor cell line models, leaving these inaccurate for
deductions regarding clinical response. Similarly, despite the
remarkable progress in generation of humanized mouse models,
mouse biology does not allow for an authentic model of human
tumors to be generated (Das Thakur et al., 2014; Hayes et al., 2014;
Malaney et al., 2014).
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The increasing research on the different cellular subtypes in
he tumor micromilieu, which communicate directly and indirectly
ith the cancer cells, has led to the development of more complex
reclinical in vitro models in early drug development (Alépée et al.,
014; Lovitt et al., 2014; Xu et al., 2014).
Using the example of human colorectal cancer in the present
tudy, 3D spheroid models of different complexity regarding cel-
ular composition were generated and the impact of clinically
elevant drug combinations, targeted and non-targeted, was  eval-
ated in each model.
. Materials and methods
.1. Cell lines and culture conditions
Five colon cancer cell lines were used for the initial experiments,
amely Caco-2 (ATCC Nr. HTB-37), DLD-1 (ATCC Nr. CCL-221), COLO
05 (ATCC Nr. CCL-222), HT-29 (ATCC Nr. HTB-38) and HCT-116
ATCC Nr. CCL-247). Cell lines were cultivated in RPMI 1640 (PAN
iotech, Aidenbach, Germany) supplemented with 10% FBS (PAN
iotech, Aidenbach, Germany) and 2 mM L-Glutamin (PAN Biotech,
idenbach, Germany). Primary cancer associated ﬁbroblasts of
olorectal origin were cultured in MEM  (PAN Biotech, Aidenbach,
ermany) supplemented with 20% FBS and 0.26 M Amphotericin
 (Biochrom, Berlin, Germany). DMEM/F12 medium (PAN Biotech,
idenbach, Germany) supplemented with 10% FBS (PAN Biotech,
idenbach, Germany), 2× MEM  non-essential amino acid solution
PAN Biotech, Aidenbach, Germany), 2× MEM  vitamin solution
PAN Biotech, Aidenbach, Germany), 0.14 mM Ampicillin (ratio-
harm, Ulm, Germany), 0.26 M Amphotericin B (Biochrom, Berlin,
ermany), 7.54 M Ciproﬂoxacin (Fresenius Kabi, Bad Homburg,
ermany), 50 g/ml Gentamicin (ratiopharm, Ulm, Germany) and
.29 mM Metronidazol (B. Braun Melsungen, Melsungen, Germany)
as used for primary colorectal cancer cells isolated from tissue
amples. All cells were incubated under standard culture conditions
37 ◦C, 5% CO2). Expansion and passaging of adherent cells were
erformed by detachment with a 0.05% trypsin/0.53 mM EDTA
olution (PAN, Aidenbach, Germany). To determine cell number and
ell viability, 0.4% trypan blue solution (Sigma–Aldrich, Steinheim,
ermany) was used in a ratio of 1:1 for the trypan blue exclusion
est.
.2. Tissue and blood samples
The study was conducted according to the Declaration of
elsinki Principles and was approved by the local ethics committee.
issue and blood samples were obtained with the informed consent
f the three healthy donors (blood) and the 16 cancer patients (tis-
ue). Samples were handled and stored according to standard bio
anking guidelines with special focus on short ischemic times of
ess than 30 min. Tissue samples were used for ﬁbroblast isolation
s well as spheroid preparation and peripheral blood mononuclear
ells (PBMCs) were isolated from donated blood samples.
.3. Isolation of PBMCs
PBMCs were isolated according to the standard Ficoll den-
ity gradient centrifugation method (Mallone et al., 2011). Brieﬂy,
ithium heparin blood samples (15 ml)  were ﬁltered through a
00 m cell strainer and the strainer washed once using DPBS
PAN Biotech, Aidenbach, Germany) to obtain a ﬁnal volume of
0 ml.  Two separate tubes were prepared with Ficoll-Paque Plus (GE
ealthcare, Little Chalfont, UK) and overlaid with the blood/DPBS
ixture in a 1:1 ratio. Following centrifugation (30 min, 497 g,
1 ◦C) the interphase was transferred to a new tube and washedechnology 205 (2015) 14–23 15
with primary cell culture medium. After determination of the via-
bility the isolated PBMCs were resuspended in primary cell culture
medium and used for homotypic and co-culture experiments.
2.4. Isolation of primary cancer-associated ﬁbroblasts of
colorectal origin
Primary human ﬁbroblasts were isolated similar to Herrera
et al. (2013b). Brieﬂy, fresh primary colorectal tumor samples
were mechanically and enzymatically digested using collagenase
(Sigma–Aldrich, Steinheim, Germany). The single cell suspension
was transferred into 1% sterile gelatin biocoated cell culture ﬂasks
and cultured under standard conditions as described above. The
medium was  renewed twice a week to remove tissue debris. For
experiments ﬁbroblasts between passages three and eight were
used.
2.5. Spheroid preparation
2.5.1. The tumor cell line spheroid model
Spheroids were generated as previously described (Mayer et al.,
2001). Brieﬂy, monolayer cultures of tumor cell lines were allowed
to reach a minimal conﬂuency of 90% for spheroid culture. The via-
bility and the cell number of the cell suspensions used for spheroid
culture were assessed. Only cell suspensions with a viability of at
least 90% were used for spheroid culture. For spheroid formation,
5 × 104 vital cells per well in either 100 l or 50 l per well were
seeded in a 96 well microtiter plate and cultured for 48 h at standard
culture conditions as mentioned above.
2.5.2. 3D co-culture of tumor cell lines with stromal cells
For co-culture experiments with ﬁbroblasts isolated from pri-
mary colorectal cancer samples, a cell suspension consisting of an
equal number of tumor cells and primary cancer-associated ﬁbro-
blasts of colorectal origin were used for spheroid formation. Vital
cells were seeded at a density of 5 × 104 per well.
Co-culture experiments with PBMCs were performed using
homotypic tumor cell line spheroids. 5 × 104 freshly isolated PBMCs
were added per well to pre-formed spheroids 48 h after tumor cell
seeding simultaneously with the drugs used for the experiments.
2.5.3. Heterotypic spheroids from cancer tissue
Surgical tissue resectates were dissected and cancer tissue sam-
ples provided by pathologists of the University Hospital LMU,
Germany. After macroscopic removal of the non-tumorous tissue
and the performance of several washing steps, the tumor tissue
was mechanically and enzymatically digested with Liberase TM
(Roche Applied Science, Basel, Switzerland) according to the manu-
facturer’s protocol in FBS free medium until the extracellular matrix
was almost entirely digested and all cell types were isolated to
obtain a single cell suspension. The digestion progress was micro-
scopically monitored every 30 min. The enzymatic reaction was
terminated by adding 10% FBS to the cell suspension. Most impor-
tantly, all the different cell types given in the individual cancer
tissue were retained. No cell depletion or enrichment step was
performed. The cell suspension was washed twice with primary
cell culture medium as described above and the cell number and
viability assessed before the cells were directly used for spheroid
formation. A minimal vitality of 80% was required for spheroid cul-
ture (Gaedtke et al., 2007).
2.6. Cancer therapyAfter 48 h of spheroid formation, chemotherapeutic agents and
molecular drugs were administered to the spheroids in clini-
cally relevant combinations at the peak plasma concentrations
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Table 1
Agents used in this study.
Drug Origin PPC (g/ml) Source PPC
5-Fluorouracil Pharmacy LMU  100 Fujimoto (2007)
Irinotecan Pharmacy LMU 7.7 Abigerges et al. (1995)
Oxaliplatin Pharmacy LMU  3.2 Schüll and Scheithauer (2002)
Cetuximab Pharmacy LMU  158.1 Tan et al. (2006)
Trastuzumab Pharmacy LMU  128 Bang et al. (2010)
Everolimus Selleck chemicals 0.05 Deenen et al. (2012)
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harmacy LMU  represents the Pharmacy of the University Hospital of the Ludwig-M
s published in dose ﬁnding phase I clinical trials (FO = 5-
uorouracil + oxaliplatin, FI = 5-ﬂuorouracil + SN38 (active metabo-
ite of irinotecan), FOC = FO + Cetuximab, FIC = FI + Cetuximab)
Table 1). The drugs were allowed to take effect for a total of
2 h. Chemotherapeutics and the antibodies were obtained from
he pharmacy of the University Hospital LMU  (Munich, Germany).
orinostat and Everolimus were bought from Selleck Chemicals
Houston, TX, USA) and SN38 was obtained from Sigma–Aldrich
Steinheim, Germany).
Medium and solvent controls were included in each experi-
ent; solvent amount was adapted to the treatment combination
ith the highest vehicle proportion in each experiment.
.7. Determination of cell viability following treatment
The viability of the treated tumor cell line spheroids was
ssessed using a solution of 3.9 mM CellTiter 96® AQueous MTS
eagent Powder (Promega, Fitchburg, WI,  USA) and 0.14 mM
henazine methosulfate (Sigma–Aldrich Steinheim, Germany) in
PBS (PAN Biotech, Aidenbach, Germany). The solution was added
o the spheroids following 72 h of treatment in a ratio of 1:5
one volume part reagent to ﬁve volume parts well content) and
ncubated at the culture conditions mentioned above for 6 h. The
bsorption of the well content was measured using a Tecan Ultra
84 multiplate reader (Tecan, Crailsheim, Germany) at 492 nm
sing 650 nm as reference wavelength. The cell viability of the
pheroids generated from cancer tissue was measured by CellTiter-
lo® Luminescent Cell Viability Assay (Promega, Fitchburg, WI,
SA) according to manufacturer’s protocol 72 h after drug adminis-
ration with a Tecan Ultra 384 multiplate reader (Tecan, Crailsheim,
ermany).
.8. Data analysis and statistics
Relative treatment efﬁcacy was expressed as percent of the
ppropriate solvent control. To evaluate the cellular interaction in
he co-culture models, expected results were calculated as refer-
nce. Under the assumption that no cellular interaction occurred
n the co-culture systems, the theoretical cellular inhibition was
alculated as the mean of the cell viability results of each homo-
ypic culture model. For statistical analysis the Student’s t-test
able 2
he tumor cell line spheroid model treated with standard chemotherapy.
Cell line Locationa FO 
Caco-2 Primary 21.91 ± 5.6
DLD-1  Primary 49.89 ± 1.3
COLO  205 Ascites 47.32 ± 1.9
HT-29  Primary 86.81 ± 2.9
HCT-116 Primary 90.95 ± 4.5
ean residual metabolic activity after chemotherapy ± standard deviation.
O: 5-FU/oxaliplatin; FI: 5-FU/irinotecan.
a From Brattain et al. (1981), Dexter et al. (1979), Luca et al. (2013) and Semple et al. (1
b p, statistical difference between oxaliplatin-based and irinotecan-based treatment.0.5 Ramalingam et al. (2007)
ilian-University of Munich.
was conducted using SPSS Statistics version 22 (IBM, Ehningen,
Germany). p-Values <0.05 were considered signiﬁcant.
3. Results and discussion
3.1. The tumor cell line spheroid model
Five human colon cancer cell lines were analyzed in the homo-
typic tumor cell line spheroid model to assess their respective
response to the two standard chemotherapies in colorectal cancer
(CRC) 5-ﬂuorouracil (5-FU) combined with either oxaliplatin (FO)
or irinotecan (FI). Caco-2 cell line spheroids were found sensitive
to both standard chemotherapies showing a higher response to FO
compared to FI. DLD-1 and COLO 205 cell line spheroids were iden-
tiﬁed as partially sensitive to FO and FI to the same extent, while
HT29 and HCT-116 cell line spheroids were each resistant to both
standard chemotherapies (Table 2). In addition, Cetuximab com-
bination therapy approved for the treatment of advanced CRC was
considered (Van Cutsem et al., 2010; Labianca et al., 2013). Although
induction of ADCC by Cetuximab is not possible in this experimental
setup, metabolic inhibition of cancer cells should be possible due to
less EGFR signaling. Combination therapy of Cetuximab with both
FO and FI each showed an increase in the treatment response in
Caco-2 and slightly in DLD-1 cell line spheroids, while no impact
was observed in COLO 205 spheroids. The treatment resistance
observed earlier in HT-29 and HCT-116 spheroids was not lessened
through the addition of Cetuximab treatment (Table 2). No evident
relationship between beneﬁt from Cetuximab therapy and KRAS
gene mutation status of the cancer cells was  observed although
both wild type and the G13D mutated KRAS gene have been shown
to result in a successful Cetuximab treatment (De Roock et al., 2010)
(Table 3).
The apparent lack of correlation between Cetuximab efﬁcacy in
the tumor cell line model in vitro and KRAS status of the cell lines
used resembles the clinical response rate of current clinical trials
with CRC patients (Sorich et al., 2014). A reason for this missing
relation might also be the inability of a homotypic cell line model
to induce antibody-dependent cellular cytotoxicity (ADCC). This
fact, and reports that the human tumor microenvironment seems
to have a major impact on drug response of cancer cells (Correia
and Bissell, 2012; Kharaishvili et al., 2014), indicates that reliable
FI pb
5 49.92 ± 7.99 0.001
3 49.41 ± 4.81 0.879
6 46.93 ± 4.67 0.922
1 94.52 ± 0.53 0.018
6 83.08 ± 3.16 0.054
978).
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Table  3
The tumor cell line spheroid model treated with standard chemotherapy combined with Cetuximab.
Tumor cell line KRAS statusa Oxaliplatin-based Irinotecan-based
FO FOC pb FI FIC pb
Caco-2 wt  21.91 ± 5.65 12.99 ± 2.43 0.031 49.92 ± 7.99 28.24 ± 7.51 0.004
DLD-1 mut  49.89 ± 1.33 46.52 ± 2.01 0.058 49.41 ± 4.81 40.35 ± 2.66 0.038
COLO 205 wt  47.32 ± 1.96 45.66 ± 1.26 0.379 46.93 ± 4.67 44.14 ± 2.68 0.514
HT-29 wt  86.81 ± 2.91 83.43 ± 3.21 0.226 94.52 ± 0.53 86.06 ± 3.37 0.021
HCT-116 mut  90.95 ± 4.56 97.92 ± 4.09 0.097 83.08 ± 3.16 94.86 ± 2.47 0.003
M d type
FIC (FI
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cean residual metabolic activity after chemotherapy ± standard deviation. Wt,  wil
a From Gaur et al. (2014) and Luca et al. (2013).
b p, statistical difference between FO and FOC (FO + Cetuximab) as well as FI and 
eductions to clinical response rates are only possible to a limited
xtent with this model. While the 3D model is standardized and
asily reproducible, the gap between in vitro treatment efﬁcacy and
linical response remains. Thus, treatment experiments were per-
ormed with mixed cancer spheroid cultures to study the effect of
he tumor microenvironment mediated by either the immune cells
Mitchem et al., 2013; Chanmee et al., 2014) or the ﬁbroblasts (Fang
t al., 2014; Kharaishvili et al., 2014) on treatment efﬁcacy in vitro.
ig. 1. Microscopic images of spheroids with different cellular composition. Homotypic s
o-cultured with PBMCs and (D) heterotypic co-culture spheroid consisting of equal amo
rimary tumor tissue spheroids of (E) patient tumor sample #15 and (F) sample #16. Sp
ulture. Bar length: 200 m.; mut, KRAS mutation G13D.
 + Cetuximab).
3.2. Co-culture experiments of the tumor cell line spheroid model
with PBMCs
Homotypic Caco-2 and DLD-1 tumor spheroids were co-
cultured with freshly isolated PBMCs. The immune cells attached
to the spheroid hull after introduction to the culture system
(Fig. 1A and B). Chemotherapies were effective to the same extent
against homotypic Caco-2 spheroids and PBMCs alone in single cell
pheroids of the cell lines (A) DLD-1 and (C) Caco-2. (B) Homotypic DLD-1 spheroid
unts of Caco-2 cells and primary tumor associated ﬁbroblasts of colorectal origin.
heroids shown consisted of 5 × 104 cells, images were taken after 48 h of spheroid
18 O.I. Hoffmann et al. / Journal of Biotechnology 205 (2015) 14–23
Fig. 2. Relative cell viability of homotypic spheroid and PBMC co-cultures after 72 h of treatment with the standard chemotherapies FO (5-ﬂuorouracil plus oxaliplatin) and
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bI  (5-ﬂuorouracil plus SN-38) without and with Cetuximab (FOC and FIC) in peak pl
ach  co-cultured after 48 h with PBMCs in a ratio of 1:1. Homotypic Caco-2 and DL
ines  represent the expected mean values of the heterotypic co-cultures assuming t
uspension culture. In both culture systems FO inhibited cellular
iability more than FI, and in addition FOC was slightly more
ffective than FO. The only difference between both homotypic
odels regarding response to chemotherapy was observed in the
fﬁcacy of FIC compared to FI. While the addition of Cetuximab to FI
educed cell viability in the tumor spheroid model, PBMCs did not
eact differently (Fig. 2A). The only experimental result in the co-
ulture model differing from the calculated co-culture results was
 slight induction of resistance to FO and FOC with no effect on their
elative response compared to each other. The reduced sensitivity
o FIC therapy observed in the co-culture system is a result of the
arge difference in reactivity between the tumor spheroids and the
BMCs but not a true co-culture effect since the experimentally
ssessed treatment efﬁcacy of the co-culture model only differed
egligibly from the expected response without cellular interaction
Fig. 2A). The DLD-1 spheroids were less sensitive to FO therapy
ompared to Caco-2 spheroids and no difference between sensi-
ivity to FO and FI were observed. While the addition of Cetuximab
o FO had no beneﬁcial effect, a slightly improved response to
IC was observed in homotypic DLD-1 spheroids. The PBMC
uspension cultures reacted similar to the earlier experiment
ith one exception, FIC was superior to FI regarding metabolicnhibition. As already observed for Caco-2 spheroids plus PBMCs,
he co-culture system of DLD-1 spheroids with PBMCs was again
ore resistant to FO than in the homotypic models. Although no
eneﬁt of Cetuximab addition to FO was observed in homotypicconcentration. Spheroids were generated of the cell lines (A) Caco-2 and (B) DLD-1,
heroids as well as PBMC suspension cultures were performed for reference. Black
 interaction between the different cell types occurs.
DLD-1 spheroid and PBMC cultures, less induction of resistance
was observed in the co-culture system for FOC compared to FO,
resulting in a signiﬁcant beneﬁt of Cetuximab (p = 0.030). Besides
resistance, a chemo-sensitizing effect to FI was induced by the
addition of immune cells to tumor cell line spheroids. Here,
the addition of Cetuximab resulted in a signiﬁcantly increased
resistance of the co-culture system to FIC (Fig. 2B, p = 0.005).
The well-documented modulating inﬂuence of different
immunologic cell types on the therapeutic susceptibility of tumor
cells (Katz and Shaked, 2014; Klemm and Joyce, 2014; Yang
et al., 2015) was  reﬂected in the co-cultured experiments with
homotypic tumor cell line spheroids and PMBCs from healthy
donors. While a major role has been described for TILs, TAMs and
unconventional lymphocytes characterized by intensive recipro-
cal interactions with the cancer cells, freshly isolated PBMCs from
healthy donors although not able to fully imitate the tumor–host
relationship were able to recapture this inﬂuence on treatment
response. On the other hand, the co-culture model of tumor cell line
spheroids with PBMCs was  still more resistant to FO therapy than
observed clinically in chemo-naïve CRC patients, which allows only
a limited accuracy in deducing clinical response to drug treatment.
This was  further supported by the fact that phenotype and func-
tionality are reported to be highly different between PBMCs and
TILs (Santin et al., 2001). Although a ratio of 1:1 was used between
tumor cells and PBMCs in the co-culture experiments, the fact that
the PBMCs were not integrated into the spheroid in a large quantity
O.I. Hoffmann et al. / Journal of Biotechnology 205 (2015) 14–23 19
Fig. 3. Relative cell viability of heterotypic co-culture spheroids consisting of equal amounts of Caco-2 cells and primary tumor associated ﬁbroblasts of colorectal origin
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n  peak plasma concentration. Experiments with homotypic Caco-2 as well as hom
epresent the expected mean values of the heterotypic co-cultures assuming that n
eﬂects the reduced number of immune cells described in primary
olon cancer tissues (Pernot et al., 2014) and is further reﬂected by
he immunoscore (Galon et al., 2014). Careful considerations are
herefore necessary in the choice for and the implementation of the
ppropriate preclinical model in cell-based immune assays, which
re widely used in both academic and pharmaceutical research.
.3. The heterotypic tumor cell line spheroid model of tumor cell
ines co-cultured with ﬁbroblasts isolated from primary human
RC tissue samples
Heterotypic tumor cell line spheroids were generated by co-
ulturing the Caco-2 tumor cells with primary human cancer
ssociated ﬁbroblasts of colorectal origin during spheroid forma-
ion. The introduction of CAFs resulted in more compact spheroids
Fig. 1C and D) when considering the large cell size of primary
broblasts. Homotypic Caco-2 tumor spheroids showed a simi-
ar response to treatment compared to earlier experiments. FO
nhibited cellular viability signiﬁcantly more than FI and the
ffect of both therapies could be improved upon by the addi-
ion of Cetuximab in both cases (Figs. 2A and 3). Contrary to the
esults of PBMC suspension cultures, spheroids consisting of tumor-
ssociated ﬁbroblasts on the other hand were almost completely
esistant to treatment.
Similar to the observations made in the co-culture experiments
ith homotypic Caco-2 tumor spheroids and PBMCs, a decreased
ensitivity to FOC but not FO was observed in the heterotypic Caco-2
nd CAF spheroid co-culture model when compared to the expected
o-culture results. Since the ﬁbroblast spheroids were already
lmost entirely resistant to FOC treatment, the observed resistance
nduction can to a large part be attributed to less chemosensitive
aco-2 tumor cells. Contrary to this observation, the 3D co-culture
f Caco-2 cells and primary human ﬁbroblasts of CRC origin induced
 signiﬁcant sensitization to FI and FIC beyond the sensitivity of
he homotypic Caco-2 spheroids although the CAF spheroids were
lmost entirely resistant to both treatments, suggesting one or both
ell types to become more susceptible to both treatments. Also, no
eneﬁt was observed by the addition of Cetuximab to both FO and
I although the homotypic Caco-2 tumor spheroids were suscep-
ible to Cetuximab (Fig. 3). In summary, the tumor cell line and
AF spheroid co-cultures allowed interactions between both cell
ypes which ultimately effected the sensitivity of the spheroids to
reatment.atin) and FI (5-ﬂuorouracil plus SN-38) without and with Cetuximab (FOC and FIC)
c tumor associated ﬁbroblast spheroids were performed for reference. Black lines
raction between the different cell types occurs.
The observed results are in line with other publications which
show that the ﬁbroblastic niche has a profound impact on the
therapeutic response of tumor cells. Cell adhesion and soluble
factors secreted by the ﬁbroblasts have been described to con-
tribute to drug resistance in cancer (e.g. Fang et al., 2014). CAFs
interact with different cell types of the tumor microenvironment
on multiple levels (Huang et al., 2014; Mahale et al., 2015; Mink
et al., 2010). Their functional heterogeneity allows the CAFs to be
involved in tumor cell survival, proliferation, invasion and metasta-
sis (e.g. Herrera et al., 2013a). Similar to the results of the co-culture
experiments with homotypic tumor cell line spheroids with PBMCs,
the observations made in the heterotypic spheroid model of tumor
cell lines and primary human tumor associated ﬁbroblasts of colo-
rectal origin underline the relevance of various factors mediated
by the tumor microenvironment in patient tumors, ultimately
inﬂuencing treatment response. Considering the implications of
both co-culture models, the interactions of a multitude of cell
types which cannot be recapitulated correctly in a two-component
co-culture model affect the treatment response. In addition, the
inter-patient heterogeneity regarding cellular composition can-
not be mimicked by co-culture models using cell lines. In order
to closely recapitulate the situation in cancer patients the cancer
tissue spheroid model was  developed.
3.4. The cancer tissue spheroid model
Cancer tissue spheroids were generated from 16 different
colorectal cancer patient samples. Depending on the tissue com-
position of the individual tumor, degrees of compactness varied
highly between tissue spheroids. As shown in Fig. 1, compact
spheroids were generated from patient sample #15 (Fig. 1E),
while less compact spheroids were obtained from patient tumor
sample #16 (Fig. 1F). Cancer tissue spheroids obtained from 10
CRC patients were treated with standard chemotherapy and were
sensitive to both FO and FI treatment, no complete drug resistance
was observed in the cancer tissue spheroid model in contrast to the
tumor cell line spheroid model (Fig. 4). Mean residual metabolic
activity of the spheroids was  25.5% (range: 4.55–46.25%) after FO
treatment and 31.59% (range: 1.0–56.0%, FO vs FI, p = 0.360) after
FI treatment. The extent of sensitivity to each treatment differed
from patient to patient as reﬂected by the large range of results
for FO and FI (Fig. 4). No signiﬁcant difference in susceptibility
to FO and FI was  observed for four patient cancer samples tested
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*ig. 4. Cell viability of cancer tissue spheroids after 72 h of treatment with the stand
n  peak plasma concentrations. *p < 0.05.
ith the primary cancer tissue spheroid model. FI was  signif-
cantly superior to FO in one patient sample and signiﬁcantly
ess effective compared to FO in ﬁve patient samples (Fig. 4). In
ontrast to the previous experiments conducted with colorectal
ancer cell line spheroids, the treatment responses observed in the
rimary cancer tissue spheroid model allow the conclusion that
he individuality of each patient tumor is reﬂected, if nothing else
hen by mimicking the cellular composition of the original tumor
ig. 5. Treatment efﬁcacy of the standard chemotherapies FO (5-ﬂuorouracil plus oxal
olecular drugs on cancer tissue spheroids after 72 h of treatment in peak plasma conce
B)  sample #12, combination therapies with Trastuzumab; (C) sample #13, combination t
p  < 0.05.emotherapies FO (5-ﬂuorouracil plus oxaliplatin) and FI (5-ﬂuorouracil plus SN-38)
tissue, relevant for the overall response to drug treatment.
Regarding these aspects the cancer tissue spheroid model is suit-
able for functional testing of biomarker-independent anti-cancer
activity. Thus, molecular drugs such as therapeutic antibodies
(Fig. 5A and B) and small molecules (Fig. 5C and D) reported as
promising agents in colorectal cancer (Grünwald and Rickmann,
2014; Linnekamp et al., 2014; Rolfo et al., 2014; Tampakis et al.,
2014) were also tested on individual patient samples in the cancer
iplatin) and FI (5-ﬂuorouracil plus SN-38) with and without addition of different
ntrations: (A) patient tumor sample #11, combination therapies with Cetuximab;
herapies with Vorinostat; (D) sample #14, combination therapies with Everolimus.
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Table  4
Characterization of the different 3D tumor models.
Model characteristics Tumor cell line
spheroid model
Tumor ce
co-cultur
Tumor biology
Biologic relevance Low Intermed
Presence of diverse
stromal cells
No Limited 
Tumor heterogeneity Low Intermed
Complexity Low Intermed
Technology
Large  scale
production
High Limited 
Operating expense Low Intermed
Application in drug development
Preclinical testing In vitro After in v
Clinical testing
Micromilieu directed
therapeutic response
No Yes 
Clinical translation Low Intermed
Testing ADCC No Yes 
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rdependent drugs
Testing cell therapy Allogenic Allo
issue spheroid model in addition to standard chemotherapy.
peciﬁcally, these were the histone deacetylase inhibitor Vorino-
tat approved for the treatment of cutaneous T cell lymphoma,
he mammalian target of Rapamycin (mTOR) inhibitor Everolimus
pproved for the treatment of advanced hormone receptor posi-
ive breast cancer among others and the anti-HER2/neu antibody
rastuzumab which is approved for the treatment of advanced
reast and stomach cancer. Results of exemplary patient tumor
pheroids are shown in Fig. 5. While no beneﬁt of Trastuzumab
ddition to either treatment was observed, the combination of
etuximab with standard chemotherapy signiﬁcantly improved
herapeutic response (sample #11: FO: 53.98% vs FO + Cetuximab:
1.1%, p = 0.005; FI: 57.23% vs FI + Cetuximab: 43.5, p = 0.0005,
ig. 5A) in the cancer tissue spheroid model. Vorinostat com-
ination therapy also showed a better response compared to
hemotherapy alone (sample #13: FO: 51.37% vs FO + Vorinostat:
2.68%, p = 0.021, Fig. 5C). The addition of Everolimus to standard
RC treatment options did not improve treatment response in vitro
sample #14, Fig. 5D).
The patient-derived cancer tissue spheroid model was devel-
ped to simulate the tumor microenvironment of human solid
ancers by retaining the cellular composition of the patient tumor
ithout selection of any speciﬁc cell type. The result obtained with
he tumor tissue spheroid model, especially the comparable over-
ll treatment responses to FO and FI are similar to data seen in
linical trials (Tournigand et al., 2004; Colucci et al., 2005). Mim-
cking the impact of the tumor microenvironment on drug response
ith this model allows a more effective drug development process
y identifying promising drug candidates for clinical investigation
n early drug development phases. Also, functional drug testing
ith the cancer tissue spheroid model has the potential to repre-
ent an alternative to companion diagnostics for targeted therapies,
hus simplifying patient stratiﬁcation by merging different diag-
ostic tests into one functional analysis. Despite this advantage,
he cancer tissue spheroid model has limitations. Although a num-
er of micro-environmental interactions can be recapitulated, an
ntact human capillary network is missing which is required for
he development and testing of anti-angiogenic drugs. Moreover,
rug screening requires a large number of patient tumors to
e tested to compensate for the inter-patient heterogeneity in
egard to treatment response which in turn requires a lot moreechnology 205 (2015) 14–23 21
ll line spheroid model
ed with primary stromal cells
Primary tumor tissue spheroid
model
iate High
High
iate High
iate High
Limited
iate High
ivo After in vivo
Identiﬁcation of the most
responsive tumor type
Identiﬁcation of the most
effective combination therapy
Companion diagnostics
Yes
iate High
Yes
 Autologous
time for tumor sample recruitment compared to tumor cell line
models.
4. Conclusions
Clinically relevant and validated preclinical models that allow
reliable deductions to clinical response represent an unmet need
in early drug development. These models should simulate human
tumor biology, predict clinical outcome and thus have the abil-
ity to identify the most promising treatment option. Engineering
the ideal biomimetic preclinical test system is very challenging,
the human tumor microenvironment and in this context its inﬂu-
ence on treatment response is particularly difﬁcult to reproduce.
The comparison of different 3D in vitro models reported in this
study revealed the cancer tissue spheroid model to be superior to
homotypic and co-culture spheroid models using tumor cell lines
regarding comparability to clinical efﬁcacy of the drug combina-
tions. The cancer tissue spheroids directly prepared from patient
tumors closely resemble the human tumor stroma signature. In
more detail, the human cancer tissue spheroid model is superior
to the gold standard in oncological drug testing, the subcutaneous
xenograft mouse model, concerning inter-species difference, tumor
heterogeneity (which is lost in the mouse model) and proliferation
activity (which is unnaturally high in the mouse model). On the
other hand, the missing vascular system, the heterogeneity of drug
efﬁcacy from patient to patient as well as tumor sample acquisition
difﬁculties among other factors limit wide-spread practical appli-
cation of the system. Thus, the tumor tissue spheroid model can
be used in small cohorts for the evaluation of drug candidates in
later stages of preclinical drug screening supplementary to in vivo
preclinical animal experiments, ﬁne-tuning the drug development
process before transfer to clinical investigation. For applications
in earlier development phases, tumor cell line spheroid models
either homotypic or in co-culture settings might be the preferable
choice due to easier reproducibility, less inter-experiment variabil-
ity and easy access to most of the established cell lines. Also, one of
the present limitations of the heterotypic models presented here
is the difﬁculty in determining the impact of treatment on each
cell type individually out of a cell mixture in the spheroid. FACS
analysis has its limitations in this context because a large quantity
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f cells is required and a standardized high-throughput implemen-
ation is difﬁcult. Cell sorting with magnetic beads or antibodies
ight be a preferable method, ideally implemented using neg-
tive selection of the relevant cell type. In conclusion, although
urther technical optimization is required, the implementation of
pheroid models with different complexity in early drug discovery
inked with the correct choice of model for the experiments rep-
esents a key technology for improving the drug screening process
Table 4).
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